• Stem Cell Research
  
  
• Medicare Coverage of DXA Bone Density Testing in Men
  
  
• Endocrine-Disrupting Chemicals
  
  
• Bioequivalence of Sodium Levothyroxine
  
  
• Steroid Abuse
  
  
• Biomedical Research Funding
  
  
• Access to Affordable and Adequate Diabetes Supplies
  
  
• Monitoring and Reporting Drug Shortages
  
  
• Bioidentical Hormones 
  
  
• Pay-for-Performance 
  
  
• Clinical Trial Registries  

Other Society Statements 

• FDA Advisory Committee Decision on Avandia
  
  
• Presentations from FDA Advisory Committee hearings on Avandia
  
  
• Joint Statement on Potential Cardiovascular Risks Associated with Rosiglitazone
  
  
• Joint Statement on Radioactive Precautions Following Radioactive Iodine Therapy
  
  
• Comments to CMS on EHR Meaningful Use
  
  
• Study Findings Related to the Treatment of Hypertension in Patients with Diabetes
  
  
• Society Statement on Long-Term Use of Bisphosphonates
  
  
• The Endocrine Society Statement in Response to the Senate Finance Committee Report on Avandia
  
  
• Society Recommends Against Altering Blood Glucose Control Goals
  
  
• The Endocrine Society Statement on the Use of A1C for Diabetes Diagnosis
  
  
• Lantus (Insulin Glargine) Statement for Patients 
  
  
• Statement for Providers on Potential Association of Insulin Glargine with Malignancy
  
  
• Guiding Principles for Health Reform
  
  
• The Endocrine Society Statement to Providers on the Report Published in the New England Journal of Medicine on NICE-SUGAR
  
  
• The Endocrine Society Statement on ACCORD Trial
  
  
• Joint Statement on Levothyroxine and Thyroxine
  
  
• Statement to Providers on the Report Published in the New England Journal of Medicine on Avandia
  
  
• Summary of Medicare Reform Legislation

Position Statements Under Review

No position statements are currently open for review.